Actively Recruiting
Phase III Study of MG-K10 Humanized Antibody Injection for Adults with Prurigo Nodularis Randomized, Double-Blind, Placebo-Controlled Treatment Over 56 Weeks
Led by Shanghai Mabgeek Biotech.Co.Ltd · Updated on 2025-04-18
160
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a humanized MG-K10 monoclonal antibody injection in adults with prurigo nodularis, a chronic skin condition. This Phase III study is randomized, double-blind, and placebo-controlled, aiming to compare the treatment against placebo over a long period. The study involves about 160 participants aged 18 to 80 years with a diagnosis of prurigo nodularis for at least 3 months and significant itch severity. Participants receive subcutaneous injections every four weeks for a total of 56 weeks. The study includes a screening period of 1 to 4 weeks, followed by a 24-week double-blind treatment phase, then a 24-week maintenance treatment phase, and finally an 8-week follow-up period. Some participants initially receiving placebo will switch to MG-K10 treatment after 24 weeks. During the study, participants will have regular assessments including itch severity scores, skin condition evaluations, quality of life, and mental health questionnaires. Researchers will monitor safety, drug levels, immune response, and treatment effects throughout the 56 weeks. The primary outcome is the proportion of subjects achieving a reduction in itch intensity by week 24, with secondary measures tracking skin scores and other symptoms through week 56.
CONDITIONS
Brief Title
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
Research Team
X
xiaofeng xiao Cai, bachelor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here